Ananth K. Vellimana

Ananth K. Vellimana

Auto-generated profile, based on publicly available information

Ananth K. Vellimana

Department of Neurosurgery (A.V., D.S.L.), Washington University in St. Louis, MO

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2023 in Stroke
Verified
Journal Article
Closed access
PDF file
DLDavid C. Lauzier
David C. Lauzier
KJKeshav Jayaraman
Keshav Jayaraman
JYJane Y. Yuan
Jane Y. Yuan
DDDeepti Diwan
Deepti Diwan
AVAnanth K. Vellimana
Ananth K. Vellimana
GZGregory J. Zipfel
Gregory J. Zipfel
Aneurysmal subarachnoid hemorrhage is a devastating condition causing significant morbidity and mortality. While outcomes from subarachnoid hemorrhage have improved in recent years, there continues to be significant interest in identifying therapeutic targets for this disease. In particular, there has been a shift in emphasis toward secondary brain injury that develops in the first 72 hours after subarachnoid hemorrhage. This time period of interest is referred to as the early brain injury period and comprises processes including microcirculatory dysfunction, blood-brain-barrier breakdown, neuroinflammation, cerebral edema, oxidative cascades, and neuronal death. Advances in our understanding of the mechanisms defining the early brain injury period have been accompanied by improved imaging and nonimaging biomarkers for identifying early brain injury, leading to the recognition of an elevated clinical incidence of early brain injury compared with prior estimates. With the frequency, impact, and mechanisms of early brain injury better defined, there is a need to review the literature in this area to guide preclinical and clinical study.

1 January 2011 in Molecular Neurodegeneration
Verified
Journal Article
Open access
PDF file
BHByung H Han
Byung H Han
MZMeng-liang Zhou
Meng-liang Zhou
AVAnanth K Vellimana
Ananth K Vellimana
EMEric Milner
Eric Milner
DKDavid H Kim
David H Kim
GZGregory J Zipfel
Gregory J Zipfel
Cerebral amyloid angiopathy (CAA) is characterized by deposition of fibrillar amyloid β (Aβ) within cerebral vessels. It is commonly seen in the elderly and almost universally present in patients with Alzheimer's Disease (AD). In both patient populations, CAA is an independent risk factor for lobar hemorrhage, ischemic stroke, and dementia. To date, definitive diagnosis of CAA requires obtaining pathological tissues via brain biopsy (which is rarely clinically indicated) or at autopsy. Though amyloid tracers labeled with positron-emitting radioligands such as [11C]PIB have shown promise for non-invasive amyloid imaging in AD patients, to date they have been unable to clarify whether the observed amyloid load represents neuritic plaques versus CAA due in large part to the low resolution of PET imaging and the almost equal affinity of these tracers for both vascular and parenchymal amyloid. Therefore, the development of a precise and specific non-invasive technique for diagnosing CAA in live patients is desired.

7 April 2017 in Epilepsia
Verified
Journal Article
Closed access
PDF file
MSMatthew D. Smyth
Matthew D. Smyth
AVAnanth K. Vellimana
Ananth K. Vellimana
EAEishi Asano
Eishi Asano
SSSandeep Sood
Sandeep Sood

30 October 2017 in Annals of Clinical and Translational Neurology
Verified
Journal Article
Open access
PDF file
AVAnanth K. Vellimana
Ananth K. Vellimana
MZMeng-liang Zhou
Meng-liang Zhou
ISItender Singh
Itender Singh
DADiane J. Aum
Diane J. Aum
JNJames W. Nelson
James W. Nelson
GZGregory J. Zipfel
Gregory J. Zipfel
Objective: Delayed cerebral ischemia (DCI) is an independent risk factor for poor outcome after aneurysmal subarachnoid hemorrhage (SAH) and is multifactorial in etiology. While prior studies have suggested a role for matrix metalloproteinase‐9 (MMP‐9) in early brain injury after SAH, its contribution to the pathophysiology of DCI is unclear.Methods: In the first experiment, wild‐type (WT) and MMP‐9−/− mice were subjected to sham or endovascular perforation SAH surgery. In separate experiments, WT and MMP‐9−/−mice were administered vehicle or minocycline either pre‐ or post‐SAH. All mice underwent assessment of multiple components of DCI including vasospasm, neurobehavioral function, and microvessel thrombosis. In another experiment, rabbits were subjected to sham or cisterna magna injection SAH surgery, and administered vehicle or minocycline followed by vasospasm assessment.Results: MMP‐9 expression and activity was increased after SAH. Genetic (MMP‐9−/− mice) and pharmacological (pre‐SAH minocycline administration) inhibition of MMP‐9 resulted in decreased vasospasm and neurobehavioral deficits. A therapeutically feasible strategy of post‐SAH administration of minocycline resulted in attenuation of multiple components of DCI. Minocycline administration to MMP‐9−/− mice did not yield additional protection. Consistent with experiments in mice, both pre‐ and post‐SAH administration of minocycline attenuated SAH‐induced vasospasm in rabbits.Interpretation: MMP‐9 is a key player in the pathogenesis of DCI. The consistent attenuation of multiple components of DCI with both pre‐ and post‐SAH administration of minocycline across different species and experimental models of SAH, combined with the excellent safety profile of minocycline in humans suggest that a clinical trial in SAH patients is warranted.

22 December 2013 in Acta Neurochirurgica
Verified
Journal Article
Closed access
PDF file
AVAnanth K. Vellimana
Ananth K. Vellimana
DDDavid J. Daniels
David J. Daniels
MSManish Narendra Shah
Manish Narendra Shah
GZGregory J. Zipfel
Gregory J. Zipfel
GLGiuseppe Lanzino
Giuseppe Lanzino

19 October 2021 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
DDDeepti Diwan
Deepti Diwan
AVAnanth K. Vellimana
Ananth K. Vellimana
DADiane J. Aum
Diane J. Aum
JCJulian Clarke
Julian Clarke
JNJames W. Nelson
James W. Nelson
GZGregory J. Zipfel
Gregory J. Zipfel
Background: Many therapies designed to prevent delayed cerebral ischemia (DCI) and improve neurological outcome in aneurysmal subarachnoid hemorrhage (SAH) have failed, likely because of targeting only one element of what has proven to be a multifactorial disease. We previously demonstrated that initiating hypoxic conditioning before SAH (hypoxic preconditioning) provides powerful protection against DCI. Here, we expanded upon these findings to determine whether hypoxic conditioning delivered at clinically relevant time points after SAH (hypoxic postconditioning) provides similarly robust DCI protection. Methods and Results: In this study, we found that hypoxic postconditioning (8% O 2 for 2 hours) initiated 3 hours after SAH provides strong protection against cerebral vasospasm, microvessel thrombi, and neurological deficits. By pharmacologic and genetic inhibition of SIRT1 (sirtuin 1) using EX527 and global Sirt1 −/− mice, respectively, we demonstrated that this multifaceted DCI protection is SIRT1 mediated. Moreover, genetic overexpression of SIRT1 using Sirt1‐Tg mice, mimicked the DCI protection afforded by hypoxic postconditioning. Finally, we found that post‐SAH administration of resveratrol attenuated cerebral vasospasm, microvessel thrombi, and neurological deficits, and did so in a SIRT1‐dependent fashion. Conclusions: The present study indicates that hypoxic postconditioning provides powerful DCI protection when initiated at clinically relevant time points, and that pharmacologic augmentation of SIRT1 activity after SAH can mimic this beneficial effect. We conclude that conditioning‐based therapies administered after SAH hold translational promise for patients with SAH and warrant further investigation.